Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• Poly(ADP-ribose) polymerase inhibitors (PARPi) like Olaparib are crucial for treating certain cancers.
• Expanding PARPi efficacy to BRCA-proficient tumors and overcoming drug resistance remain significant challenges.

Purpose of the Study:

• To identify novel synergistic drug combinations with Olaparib for BRCA-proficient triple-negative breast cancer.
• To evaluate the potential of ruthenium(II) polypyridyl complexes (RPCs) in combination cancer therapy.

Main Methods:

• Screening of a micro-library containing commercial drugs and RPCs for Olaparib synergy.
• Testing synergistic combinations in BRCA-proficient and resistant breast cancer cell lines and spheroid models.
• Investigating mechanisms of synergy, including DNA damage and apoptosis induction.
• Assessing cytotoxicity in non-malignant cells and toxicity in zebrafish embryos.

Main Results:

• Curcumin and two novel ruthenium(II)-rhenium(I) polypyridyl metallomacrocycles demonstrated synergy with Olaparib.
• Effective combinations were observed in BRCA-proficient, Olaparib-resistant cells, and spheroid models.
• Synergy was attributed to enhanced DNA damage and apoptosis, with minimal toxicity to normal cells and embryos.

Conclusions:

• Ruthenium(II) polypyridyl metallomacrocycles represent a new class of agents for cancer combination therapy.
• This study validates the inclusion of metallo-compounds in drug synergy screening for novel cancer treatments.